We have shown that in vivo administration of phosphorothioate antisense oligonucleotides targeting IGF-IR decreased receptor protein levels and concomitantly inactivated AKT and MAPK signaling pathways leading to C4HD breast tumor growth inhibition [21]. Here, IGF1R is linked to breast neoplasm.